A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People

NCT01123915 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: Opal-HIV-Gag(c) Low Dose
BIOLOGICAL: Opal-HIV-Gag(c) Medium dose
BIOLOGICAL: Opal-HIV-Gag(c) High dose
OTHER: Dimethyl Sulfoxide

Sponsor

Medicines Development for Global Health

Collaborators

[object Object]
[object Object]